8 years of historical data (2017–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
RAPT Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7.7B | $64M | $953M | $644M | $1.0B | $477M | $603M | — | — |
| Enterprise Value | $7.5B | $-100840405 | $912M | $614M | $982M | $452M | $525M | — | — |
| P/E Ratio → | -2.27 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 421.94 | 263.85 | 94.54 | — | — | — |
| P/B Ratio | 1.56 | 0.34 | 6.48 | 2.63 | 5.40 | 4.58 | 8.24 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 402.32 | 257.55 | 89.59 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -77.1% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating Margin | — | — | — | -5618.5% | -1815.1% | -1055.4% | — | — | — |
| Net Profit Margin | — | — | — | -5490.4% | -1814.9% | -1049.0% | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -77.1% | -77.1% | -59.6% | -38.9% | -47.6% | -59.7% | -62.7% | -4538.2% | — |
| ROA | -62.8% | -62.8% | -53.1% | -36.1% | -43.6% | -52.0% | -55.8% | -60.2% | -57.8% |
| ROIC | -155.7% | -155.7% | -59.3% | -34.1% | -43.0% | -106.4% | -41.7% | -34.6% | — |
| ROCE | -79.3% | -79.3% | -63.0% | -38.9% | -46.7% | -58.3% | -62.2% | -65.9% | -62.2% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $170M exceeds total debt of $4M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.05 | 0.04 | — | — | — | 2.52 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.87 | -0.28 | -0.12 | -0.13 | -0.24 | -1.06 | 1.52 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($170M) exceeds total debt ($4M)
Short-term solvency ratios and asset-utilisation metrics
RAPT Therapeutics, Inc.'s current ratio of 4.87x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 17.77x to 4.87x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.87 | 4.87 | 7.41 | 17.77 | 20.11 | 9.84 | 8.70 | 14.01 | 14.85 |
| Quick Ratio | 4.87 | 4.87 | 7.41 | 17.77 | 20.11 | 9.84 | 8.70 | 14.01 | 14.85 |
| Cash Ratio | 4.78 | 4.78 | 7.28 | 17.51 | 19.77 | 9.50 | 8.36 | 13.74 | 14.63 |
| Asset Turnover | — | — | — | 0.01 | 0.02 | 0.04 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
RAPT Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $5M | $5M | $4M | $3M | $3M | $3M | $3M | $3M |
Compare RAPT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| RAPTYou | $8B | -2.3 | — | — | — | — | -77.1% | -155.7% | — |
| ARGX | $47B | 60.0 | — | — | 89.6% | -1.0% | 17.4% | -0.5% | — |
| CANF | $14B | -4.4 | — | — | 100.0% | -1206.2% | -134.9% | -448.3% | — |
| AKTX | $13B | -0.0 | — | — | — | — | -179.9% | -172.5% | — |
| ABVX | $10B | -36.7 | — | — | 100.0% | -1602.9% | -149.0% | — | — |
| KYMR | $7B | -24.8 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
| PTGX | $6B | -44.9 | — | 99.9 | — | — | -20.2% | -21.8% | — |
| IMVT | $6B | -10.2 | — | — | — | — | -62.5% | — | — |
| TGTX | $5B | 200.6 | 114.4 | — | 88.3% | 12.7% | 12.2% | 13.3% | 6.0 |
| APGE | $4B | -21.2 | — | — | — | — | -33.2% | -38.3% | — |
| KNSA | $3B | 59.3 | 41.0 | 133.6 | — | 11.4% | 23.6% | 17.1% | 0.1 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 8 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how RAPT stacks up against sector leader argenx SE.
Start ComparisonRAPT Therapeutics, Inc.'s current P/E ratio is -2.3x. This places it at the 50th percentile of its historical range.
RAPT Therapeutics, Inc.'s return on equity (ROE) is -77.1%. The historical average is -57.6%.
Based on historical data, RAPT Therapeutics, Inc. is trading at a P/E of -2.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.